WO2007034280A3 - Composition and method for prevention of influenza - Google Patents

Composition and method for prevention of influenza Download PDF

Info

Publication number
WO2007034280A3
WO2007034280A3 PCT/IB2006/002566 IB2006002566W WO2007034280A3 WO 2007034280 A3 WO2007034280 A3 WO 2007034280A3 IB 2006002566 W IB2006002566 W IB 2006002566W WO 2007034280 A3 WO2007034280 A3 WO 2007034280A3
Authority
WO
WIPO (PCT)
Prior art keywords
subjects
subject
methods
allergic
diagnosed
Prior art date
Application number
PCT/IB2006/002566
Other languages
French (fr)
Other versions
WO2007034280A2 (en
Inventor
Moshe Amihood Blay
Original Assignee
Moshe Amihood Blay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moshe Amihood Blay filed Critical Moshe Amihood Blay
Publication of WO2007034280A2 publication Critical patent/WO2007034280A2/en
Publication of WO2007034280A3 publication Critical patent/WO2007034280A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Novel compositions and methods for vaccinating a subject against influenza.. The compositions and methods are based on the use a vaccine that includes an antigen that is extracted from Streptococcus pneumonia. The methods are particularly useful for vaccination of subjects who do not have an increased risk of developing pneumonia, subjects who have 4 x 109 to 11 x 109 white blood cells in a liter of blood, subjects who are not immunocompromised, subject who have functional spleen, subjects who are allergic to inactivated virus-based influenza vaccine, subjects who are allergic to eggs, subjects who are diagnosed with a Guillain-Barré syndrome, subjects who do not have cancer, leukemia, lymphoma, or multiple myeloma, subjects who do not have HIV infection, subjects who are not diagnosed with cirrhosis of the liver, subjects who are not recipients of organ transplants or bone marrow transplants, subject who do not take medications that lower immunity, and subject that are less than 65 years old.
PCT/IB2006/002566 2005-09-19 2006-09-15 Composition and method for prevention of influenza WO2007034280A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71774205P 2005-09-19 2005-09-19
US60/717,742 2005-09-19
US83018406P 2006-07-12 2006-07-12
US60/830,184 2006-07-12

Publications (2)

Publication Number Publication Date
WO2007034280A2 WO2007034280A2 (en) 2007-03-29
WO2007034280A3 true WO2007034280A3 (en) 2007-08-30

Family

ID=37889171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002566 WO2007034280A2 (en) 2005-09-19 2006-09-15 Composition and method for prevention of influenza

Country Status (1)

Country Link
WO (1) WO2007034280A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6097388B2 (en) * 2012-07-10 2017-03-15 ネピアン ブルー マウンテンズ ローカル ヘルス ディストリクト Risk stratification in influenza

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287173A (en) * 1979-09-24 1981-09-01 Merck & Co., Inc. Vaccine for dental caries
US5855901A (en) * 1995-06-07 1999-01-05 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287173A (en) * 1979-09-24 1981-09-01 Merck & Co., Inc. Vaccine for dental caries
US5855901A (en) * 1995-06-07 1999-01-05 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOWAK-WEGRZYN A.: "Serum Opsonic Activity in Infants with Sickle-Cell Disease Immunized with Pneumococcal Polysaccharide Protein Conjugate Vaccine", CLIN. AND DIAGN. LAB. IMMUNOL., vol. 7, September 2000 (2000-09-01), pages 788 - 793, XP055118493, DOI: doi:10.1128/CDLI.7.5.788-793.2000 *
SHAFINOORI S.: "Impact of Pneumococcal Conjugate vaccine and the Severity of Winter Influenza-Like Illnesses on Invasive Pneumococcal Infections in Children and Adults", THE PEDIATRIC INFECTIOUS DISEASES JOURNAL, vol. 24, January 2005 (2005-01-01), pages 10 - 16 *

Also Published As

Publication number Publication date
WO2007034280A2 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
Wade The oral microbiome in health and disease
Wei et al. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate‐related osteonecrosis of the jaw
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EP4219566A3 (en) Recombinant rsv antigens
WO2008100598A3 (en) A method for enhancing t cell response
You et al. Prevalence and diversity of S ynergistetes taxa in periodontal health and disease
WO2005052119A3 (en) Adjuvants of immune response
MX2009006178A (en) Salmonella vaccine.
AR044696A1 (en) VACCINE COMPOSITION
EP2759307A3 (en) Vaccine against Streptococci
WO2009042895A3 (en) Reagents for inducing an immune response
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
DE60143755D1 (en) GENEMATED DNA VACCINES FOR CO EXPRESSION, METHODS FOR THE PRODUCTION THEREOF AND THEIR USES
WO2002034773A3 (en) Streptococcal genes
BRPI0818718B8 (en) process of preparing a vaccine composition comprising antigen and adjuvant in the form of inverse latex of acrylic acid homopolymer
Martelet et al. Porcine dendritic cells as an in vitro model to assess the immunological behaviour of Streptococcus suis subunit vaccine formulations and the polarizing effect of adjuvants
WO2007034280A3 (en) Composition and method for prevention of influenza
NZ603854A (en) West nile virus vaccine
WO2007010399A3 (en) Purified trimeric s protein as vaccine against severe acute respiratory syndrome virus infections
WO2009077744A3 (en) Vaccines for brucellosis
WO2007086898A3 (en) Methods and compositions related to anthrax spore glycoproteins
Ljungman Infectious complications and vaccines
FI3334454T3 (en) Mycoplasma bovis compositions
Verma et al. Sphingobacterium multivorum causing fatal meningoencephalitis: a rare case report

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06795508

Country of ref document: EP

Kind code of ref document: A2